Glenmark Gets Four-Month Jump On Generic Zetia Market Under Patent Settlement
This article was originally published in PharmAsia News
Executive Summary
Glenmark Pharmaceuticals will be able to launch its generic version of Merck's Zetia (ezetimibe) four-and-a-half months before the basic compound patent expires, under a settlement of a patent infringement suit with Merck